A Phase 3 clinical trial involving insulin glargine entered recruiting status as of September 1, 2026. The study, registered as NCT07797335 and titled AMBITION 7, is described as "A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications."
According to the registration, the trial is designed to compare zenagamtide against insulin glargine in people with type 2 diabetes who also have increased risk of cardiovascular disease and who are already being treated with one to three other diabetes medications. The trial is currently listed with a status of recruiting and is in Phase 3.
No results have been posted for this study at this stage, and the event data does not include efficacy or safety outcomes. This brief reflects only the trial registration status, phase, and title as provided; it does not characterize or predict findings from the study.
Readers interested in background on insulin glargine can consult the compound overview for additional context.